DE69816103D1 - Gesteuerte freisetzung von sublingual oder bukkal verabreichten arzneistoffen - Google Patents

Gesteuerte freisetzung von sublingual oder bukkal verabreichten arzneistoffen

Info

Publication number
DE69816103D1
DE69816103D1 DE69816103T DE69816103T DE69816103D1 DE 69816103 D1 DE69816103 D1 DE 69816103D1 DE 69816103 T DE69816103 T DE 69816103T DE 69816103 T DE69816103 T DE 69816103T DE 69816103 D1 DE69816103 D1 DE 69816103D1
Authority
DE
Germany
Prior art keywords
bukal
sublingual
substances
controlled release
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69816103T
Other languages
English (en)
Other versions
DE69816103T2 (de
Inventor
Ragab El-Rashidy
Bruce Ronsen
Eldin Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pentech Pharmaceuticals Inc
Original Assignee
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals Inc filed Critical Pentech Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69816103D1 publication Critical patent/DE69816103D1/de
Publication of DE69816103T2 publication Critical patent/DE69816103T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
DE69816103T 1997-04-29 1998-04-29 Gesteuerte freisetzung von sublingual oder bukkal verabreichten arzneistoffen Expired - Lifetime DE69816103T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US841250 1997-04-29
US08/841,250 US5888534A (en) 1995-06-13 1997-04-29 Controlled release of drugs delivered by sublingual or buccal administration
PCT/US1998/008630 WO1998048781A1 (en) 1997-04-29 1998-04-29 Controlled release of drugs delivered by sublingual or buccal administration

Publications (2)

Publication Number Publication Date
DE69816103D1 true DE69816103D1 (de) 2003-08-07
DE69816103T2 DE69816103T2 (de) 2004-04-15

Family

ID=25284405

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816103T Expired - Lifetime DE69816103T2 (de) 1997-04-29 1998-04-29 Gesteuerte freisetzung von sublingual oder bukkal verabreichten arzneistoffen

Country Status (23)

Country Link
US (1) US5888534A (de)
EP (1) EP1017371B1 (de)
JP (1) JP4948691B2 (de)
CN (1) CN1135103C (de)
AR (1) AR012615A1 (de)
AT (1) ATE244000T1 (de)
BR (1) BR9808703A (de)
CA (1) CA2289260C (de)
CO (1) CO4940397A1 (de)
CZ (1) CZ292513B6 (de)
DE (1) DE69816103T2 (de)
DK (1) DK1017371T3 (de)
ES (1) ES2201487T3 (de)
HK (1) HK1031334A1 (de)
HU (1) HU225108B1 (de)
IL (1) IL132646A0 (de)
NO (1) NO995302L (de)
NZ (1) NZ501114A (de)
PL (1) PL336759A1 (de)
PT (1) PT1017371E (de)
TW (1) TW430562B (de)
WO (1) WO1998048781A1 (de)
ZA (1) ZA983548B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
JP2004513899A (ja) * 2000-11-15 2004-05-13 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 抗鬱薬誘発性的機能不全のアポモルヒネによる治療
MXPA03007081A (es) * 2001-02-08 2004-10-15 Pharmacia Corp Medicamento de accion rapida para el tratamiento de disfuncion sexual.
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
EP2258351B1 (de) * 2001-10-17 2013-06-19 Takeda Pharmaceutical Company Limited Granulate mit Lansoprazole in großer Menge
BR0307473A (pt) * 2002-02-07 2004-11-09 Pharmacia Corp Forma de dosagem farmacêutica para distribuição por via mucosa
US20060004190A1 (en) * 2002-03-19 2006-01-05 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
WO2007008752A2 (en) * 2005-07-07 2007-01-18 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
CN102056568B (zh) 2008-06-04 2013-08-21 高露洁-棕榄公司 具有气穴系统的口腔护理器具
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN101475145B (zh) * 2009-01-20 2014-10-22 同济大学 一种具有磁热和靶向药物缓释特性的水滑石及其制备方法
ES2699077T3 (es) * 2009-06-12 2019-02-07 Sunovion Pharmaceuticals Inc Apomorfina sublingual
WO2011027363A2 (en) * 2009-09-04 2011-03-10 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
EP2504019A2 (de) 2009-11-25 2012-10-03 ArisGen SA Zusammensetzung zur verabreichung über die schleimhaut mit einem komplex aus einem peptid und einer kronenverbindung und/oder einem gegenion
NZ612686A (en) 2010-12-16 2015-11-27 Cynapsus Therapeutics Inc Sublingual films
PT2706986E (pt) 2011-09-19 2015-07-07 Orexo Ab Nova composição farmacêutica resistente ao abuso para o tratamento da dependência de opiáceos
US20140256822A1 (en) * 2013-03-11 2014-09-11 Pharmaceutical Productions Inc. Transmucosal drug delivery system
EP3285771A4 (de) 2015-04-21 2018-12-05 Sunovion Pharmaceuticals Inc. Verfahren zur behandlung von morbus parkinson durch verabreichung von apomorphin an eine mundschleimhaut
WO2018112061A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
ATE189121T1 (de) * 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
NO995302L (no) 1999-12-27
DE69816103T2 (de) 2004-04-15
CA2289260A1 (en) 1998-11-05
EP1017371A4 (de) 2000-07-12
EP1017371B1 (de) 2003-07-02
CZ386099A3 (cs) 2000-04-12
ES2201487T3 (es) 2004-03-16
CZ292513B6 (cs) 2003-10-15
JP4948691B2 (ja) 2012-06-06
TW430562B (en) 2001-04-21
JP2001527546A (ja) 2001-12-25
WO1998048781A1 (en) 1998-11-05
HK1031334A1 (en) 2001-06-15
NZ501114A (en) 2001-09-28
ATE244000T1 (de) 2003-07-15
CN1135103C (zh) 2004-01-21
HUP0003405A3 (en) 2001-04-28
NO995302D0 (no) 1999-10-29
BR9808703A (pt) 2001-11-20
CN1271276A (zh) 2000-10-25
HUP0003405A2 (hu) 2001-02-28
EP1017371A1 (de) 2000-07-12
HU225108B1 (en) 2006-06-28
CO4940397A1 (es) 2000-07-24
US5888534A (en) 1999-03-30
IL132646A0 (en) 2001-03-19
ZA983548B (en) 1999-01-28
CA2289260C (en) 2008-02-12
PT1017371E (pt) 2003-10-31
DK1017371T3 (da) 2003-09-29
PL336759A1 (en) 2000-07-17
AR012615A1 (es) 2000-11-08

Similar Documents

Publication Publication Date Title
DE69816103D1 (de) Gesteuerte freisetzung von sublingual oder bukkal verabreichten arzneistoffen
DE69837906D1 (de) Insektizides proteintoxin von xenorhabus
CY2012029I2 (el) Nεα μορφη της 5-ομεπραζολης
DE69732684D1 (de) Automatische Modifizierung von Dokumentgestaltungen
DE69703446D1 (de) Feines oder subdenier faservliessubstrat
DE69725205D1 (de) Befestigung von Biomolekülen
DE69718393D1 (de) Befestigung von Biomolekülen
DE19882125T1 (de) Direkte Abscheidung von Palladium
ID24201A (id) Rekoveri komponen-komponen limbah kulit telur
DE69630603D1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DE69838482D1 (de) Verbesserungen von oder bezüglich telekommunikation
DE59804303D1 (de) Herstellung von Polyenaldehyden
ATE232199T1 (de) Polymorphe modifikationen von dofetilid
DE29703995U1 (de) Querlochziegel
DE69800956D1 (de) Zeitpunktregler
DE59813942D1 (de) Anlenking von mechanischen Betätigungszügen
DK36193D0 (da) Fremgangsmaade
DE69804782D1 (de) Isomerisierung von fluorkohlenwasserstoffen
DE69713192D1 (de) Kombination von Enzymen
DE69803309T2 (de) Rückgewinnung von gipsmaterialien
DE69838345D1 (de) Abscheidung von material
DE29712159U1 (de) Ruckhemmung
DE69834398D1 (de) Anhänger
DE29621512U1 (de) Kodierung von Steuerungen
DE29720614U1 (de) Begrenzungen von Ställen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition